By Maxx Chatsko Many companies are taking a similar approach, but no one is quite sure if it’ll help patients. Science progresses, however slowly, by testing hypotheses. Biotech investors are familiar with this concept through clinical trials. Clinical trials are how drug developers test hypotheses about the molecular drivers of disease. It often takes years and hundreds of millions of dollars to arrive at an answer. Even then, results aren’t always perfectly clear. That’s usually due to the complexity of biology and simplicity of hypotheses. For example, Huntington’s disease appears to be cau…